1. Home
  2. VEL vs OABI Comparison

VEL vs OABI Comparison

Compare VEL & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Velocity Financial Inc.

VEL

Velocity Financial Inc.

N/A

Current Price

$15.94

Market Cap

644.2M

Sector

Finance

ML Signal

N/A

Logo OmniAb Inc.

OABI

OmniAb Inc.

N/A

Current Price

$4.94

Market Cap

773.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VEL
OABI
Founded
2004
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
644.2M
773.1M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
VEL
OABI
Price
$15.94
$4.94
Analyst Decision
Hold
Strong Buy
Analyst Count
3
7
Target Price
★ $20.83
$8.33
AVG Volume (30 Days)
146.9K
★ 1.5M
Earning Date
11-04-2026
10-30-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 43.98
6.56
EPS
★ 1.88
N/A
Revenue
N/A
★ $18,666,000.00
Revenue This Year
N/A
$94.10
Revenue Next Year
$11.91
$30.33
P/E Ratio
$8.56
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$14.18
$1.35
52 Week High
$21.40
$5.45

Technical Indicators

Market Signals
Indicator
VEL
OABI
Relative Strength Index (RSI) 49.05 50.07
Support Level $14.22 $4.43
Resistance Level $18.15 $5.30
Average True Range (ATR) 0.76 0.38
MACD 0.02 -0.03
Stochastic Oscillator 27.15 51.36

Price Performance

Historical Comparison
VEL
OABI

About VEL Velocity Financial Inc.

Velocity Financial Inc is a United States-based real estate finance company. Company operates in a large fragmented market with substantial demand for financing and limited supply of institutional financing alternative The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: